Scilex Holding (SCLX) Non-Current Deffered Revenue (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Non-Current Deffered Revenue of $1.9 million for Q1 2026, down 16.99% year-over-year from $2.3 million in Q1 2025, and down 4.7% on a QoQ basis from $2.0 million in Q4 2025.
Scilex Holding (SCLX) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Non-Current Deffered Revenue for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 16.99% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 16.99% YoY), while the FY2025 annual figure was $2.0 million, down 16.63% from the prior year.
- Non-Current Deffered Revenue came in at $1.9 million for Q1 2026 at Scilex Holding, down from $2.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $5.2 million in Q1 2022, with the low at $1.9 million in Q1 2026.
- Average Non-Current Deffered Revenue over 5 years is $3.1 million, with a median of $2.8 million recorded in 2024.
- Across the five-year window, Non-Current Deffered Revenue changed 0.0% in 2022 and plunged 41.93% in 2023, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $3.4 million in 2022, then decreased by 14.53% to $2.9 million in 2023, then dropped by 15.44% to $2.4 million in 2024, then decreased by 16.63% to $2.0 million in 2025, then slipped by 4.7% to $1.9 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.9 million, $2.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.95 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 2.67 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | 3.01 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 3.26 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Jun 30, 2022 | 5.19 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Sep 30, 2021 | 5.19 Mn |
| Jun 30, 2021 | 5.19 Mn |
| Mar 31, 2021 | 5.19 Mn |